| Current Price | $0.64 | Mkt Cap | $8.0M |
|---|---|---|---|
| Open | $0.63 | P/E Ratio | -0.33 |
| Prev. Close | $0.64 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.63 - $0.68 | Volume | 51,361 |
| 52-Wk Range | $0.50 - $2.41 | Avg. Daily Vol. | 55,879 |
A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
| Current Price | $0.64 | Mkt Cap | $8.0M |
|---|---|---|---|
| Open | $0.63 | P/E Ratio | -0.33 |
| Prev. Close | $0.64 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.63 - $0.68 | Volume | 51,361 |
| 52-Wk Range | $0.50 - $2.41 | Avg. Daily Vol. | 55,879 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about CYCC.
Recs
oscillation
(76.30)
Submitted: 6/1/2015 1:40:33 AM :
Start Price:
$8.64
NASDAQ:CYCC Score:
-189.50
nev
Recs
UnstableEnabled
(< 20)
Submitted: 12/21/2013 3:30:17 AM :
Start Price:
$44.94
NASDAQ:CYCC Score:
-227.37
A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.
It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.
Sorely depressed, any good new will cause the stock to surge upward.
Recs
toegar2000
(40.24)
Submitted: 3/2/2013 10:25:20 AM :
Start Price:
$64.19
NASDAQ:CYCC Score:
-274.00
Looks good IMO
Find the members with the highest scoring picks in CYCC.
longtermgrowth09 (49.87) Score: +370.57
The Score Leader is the player with the highest score across all their picks in CYCC.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| longtermgrowth09 | 49.87 | 8/3/2010 |
|
5Y | $137.26 | -99.53% | +271.03% | +370.57 | 0 Comment | |
| mrtofoo | 24.46 | 1/7/2008 |
|
5Y | $425.66 | -99.85% | +208.94% | +308.79 | 0 Comment | |
| MFBurritoSquat | 67.33 |
|
|
1Y | $37.47 | -98.29% | +194.90% | +293.19 | 0 Comment | |
| bluebare | 28.75 | 12/7/2012 |
|
5Y | $75.63 | -99.15% | +193.86% | +293.01 | 0 Comment | |
| imrhh | < 20 | 5/7/2007 |
|
3M | $637.27 | -99.90% | +192.43% | +292.33 | 2 Comments | |
| klaracat | 32.30 | 10/22/2012 |
|
5Y | $60.93 | -98.95% | +191.54% | +290.49 | 0 Comment | |
| GenericMind5885 | 98.31 | 2/27/2015 |
|
5Y | $17.97 | -96.44% | +97.57% | +194.01 | 0 Comment | |
| IdahoInvestor | 27.58 | 8/13/2015 |
|
5Y | $7.18 | -91.08% | +99.94% | +191.03 | 0 Comment | |
| iPittytheFool | 60.41 | 10/10/2016 |
|
5Y | $5.47 | -88.30% | +93.07% | +181.37 | 0 Comment | |
| portefeuille2 | 98.77 | 4/29/2019 |
|
5Y | $0.68 | -6.51% | +42.19% | -48.70 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
